The 105th AUA annual meeting provided important research advances on several fronts. Two themes emerged across a number of presentations: utilization of various diagnostic techniques and treatment modalities (both overuse and underuse); and interrelationships among various non-urologic medical conditions.
San Francisco-The 105th AUA annual meeting provided important research advances on several fronts. Two themes emerged across a number of presentations: utilization of various diagnostic techniques and treatment modalities (both overuse and underuse)-a hot topic in the new world of health care reform; and interrelationships among various non-urologic medical conditions, including metabolic syndrome, and urologic diseases.
These themes were highlighted in the meeting's take-home messages: the key research and policy points in 27 topic areas. In this article Urology Times brings you the meeting highlights in succinct bullet points. Messages have been edited for space, and those of particular interest are highlighted in red.
Health Care Policy
Localized Prostate Cancer
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.